mrtx0902
·Code: MRTX0902
mrtx0902: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Mirati Therapeutics, Inc. (MRTX) | Phase 1 |
Clinical Trials (1)
A Phase 1 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients With Advanced Solid Tumors Harboring Mutations in the KRAS MAPK Pathway
Frequently asked questions
Who is developing mrtx0902?
mrtx0902 is being developed by Mirati Therapeutics, Inc..
How many clinical trials involve mrtx0902?
BioSniper tracks 1 clinical trial involving mrtx0902.
Get deeper analysis on mrtx0902
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis